Back to Dashboard

KRT-232-115

MPN•NCT06479135•Last updated: 2/17/2026

Recruiting

Study Design

Study Drug

Navtemadlin + Ruxolitinib

Mechanism of Action

MDM2

Sponsor

Unknown

Design

III

Control Arm

Navtemadlin(placebo) + Ruxolitinib

Criteria

Inclusion Criteria

JAK inhibitor naive

Age: Phase: III

Exclusion Criteria

Enrollment

Progress0 / 0

Contact Information

Principal Investigator

Unknown

Study Nurse

李佳玲

Contact Tel

4620